ArticleCureus2025
Management of Glaucoma in Cytomegalovirus Uveitis: A Retrospective Case Series of Surgical and Medical Approaches.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) is a double-stranded (dsDNA) virus of the herpesvirus family. Serological tests reveal signs of previous exposure to it in 40% to 100% of the general population. CMV anterior uveitis (AU) is the most common form of ocular manifestation of CMV in immunocompetent individuals. Clinically, it manifests mainly as anterior chamber (AC) inflammation, iris atrophy, and elevated intraocular pressure (IOP). In this study, we presented four cases of CMV AU with high IOP requiring different treatment modalities to control the IOP. All patients underwent AC paracentesis, and the aqueous sample sent for polymerase chain reaction (PCR) showed CMV DNA. They were treated with ganciclovir ophthalmic gel 0.15% for the infection. For IOP control, patients underwent different surgeries, namely microinvasive glaucoma surgery (MIGS) with XEN implant, augmented trabeculectomy (AT), glaucoma drainage device implantation (GDI), and transscleral cyclophotocoagulation (TSCPC). Patients were then followed up for a period ranging from six months to three years post-intervention to monitor for evidence of recurrence, IOP control, number of topical antiglaucoma medications required, and progression of glaucoma as evidenced by optical coherence tomography (OCT) retina nerve fiber layer (RNFL) and Humphrey visual field (HVF).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.